Doses, indications, and trial designs differ, but the headline pattern is consistent across multiple peer-reviewed analyses: higher GLP-1 dose drives higher GI rates, and adding GIP receptor activity (as tirzepatide does) appears to modestly buffer the diarrhea-specific signal compared to high-dose semaglutide alone
Although both help manage blood sugar, they work in different ways
Nevertheless, the clinical translation of many PEs remains limited
2nd GLP-1-Based Therapeutics Summit 2025 29th April 2025 - May 01, 2025 The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication expansion with new clinical data, new preclinical data, and 18+ expert speakers including Eli Lily, Regeneron, Roche, Novo Nordisk, Fractyl Health and more at the forefront of the field
For more information on micronutrients and phytochemicals related to cognitive decline or neurodegenerative diseases, see the article on Micronutrients for Older Adults
